Ferriprox(deferiprone)
Ferriprox (deferiprone) is a small molecule pharmaceutical. Deferiprone was first approved as Ferriprox on 1999-08-25. It is used to treat iron overload in the USA. It has been approved in Europe to treat beta-thalassemia and iron overload.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Ferriprox (generic drugs available since 2019-02-08)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| deferiprone | ANDA | 2022-08-12 |
| ferriprox | New Drug Application | 2021-11-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| iron overload | — | D019190 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DEFERIPRONE, FERRIPROX, CHIESI | |||
| 2028-04-30 | ODE-417, ODE-418, ODE-419, ODE-420, ODE-421 | ||
| 2024-04-30 | I-859 | ||
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Iron overload | D019190 | — | 5 | 2 | 4 | 3 | 14 | ||
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 4 | 3 | 4 | 3 | 11 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | 1 | 2 | — | 4 |
| Hemosiderosis | D006486 | — | 1 | 1 | 1 | — | 2 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
| Hepatic insufficiency | D048550 | — | — | — | 1 | — | 1 | ||
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 4 | 1 | — | 1 | 5 |
| Pantothenate kinase-associated neurodegeneration | D006211 | G23.0 | — | — | 2 | — | 1 | 3 | |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 2 | 1 | — | 1 | 3 |
| Hemochromatosis | D006432 | EFO_1000642 | E83.11 | — | 1 | 1 | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 1 | — | — | 1 |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | 1 | 1 | — | — | 1 |
| Iron metabolism disorders | D019189 | E83.1 | — | 1 | 1 | — | — | 1 | |
| Sensorineural hearing loss | D006319 | HP_0000407 | H90.5 | — | 1 | 1 | — | — | 1 |
| Optic atrophy | D009896 | H47.2 | — | 1 | 1 | — | — | 1 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thalassemia | D013789 | EFO_1001996 | D56 | 1 | 1 | — | — | 2 | 3 |
| Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | — | — | — | 2 | |
| Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | 1 | 2 | — | — | — | 2 |
| Dementia | D003704 | F03 | 1 | 1 | — | — | — | 1 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | D46 | — | 1 | — | — | — | 1 | |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 1 | — | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 | ||
| Asymptomatic infections | D058345 | 1 | — | — | — | — | 1 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DEFERIPRONE |
| INN | deferiprone |
| Description | Deferiprone is a member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia. It has a role as an iron chelator and a protective agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(O)c(=O)ccn1C |
Identifiers
| PDB | — |
| CAS-ID | 30652-11-0 |
| RxCUI | 11645 |
| ChEMBL ID | CHEMBL70927 |
| ChEBI ID | 68554 |
| PubChem CID | 2972 |
| DrugBank | DB08826 |
| UNII ID | 2BTY8KH53L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,527 documents
View more details
Safety
Black-box Warning
Black-box warning for: Deferiprone, Ferriprox
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,467 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more